Back to Results

OKYO Pharma (OKYO)

OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on therapies for inflammatory eye diseases and ocular pain. Its lead candidate, urcosimod, is being studied in Phase II trials for dry eye disease and neuropathic corneal pain, and is also in preclinical development for allergic conjunctivitis and uveitis. The company is additionally advancing OK-201 as a potential treatment for acute and chronic ocular pain. Incorporated in 2007 and headquartered in London, United Kingdom, OKYO Pharma’s common stock trades on the NASDAQ under the symbol OKYO.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-OKYO
$1.08
-20.3% Downside
Overvalued
$8.33
512.7% Upside
Bargain
Fair
0.0%
December 2, 2026
5.8x
70.585 M
50.778 M
0.0%
53.2%
-17.7
66.4%
Valuation • Fair Value

OKYO Pharma (NASDAQ-OKYO) Fair Value by Valuation Model

Review the available estimates for OKYO Pharma (NASDAQ-OKYO), including Comps Fair Value.

Primary Valuation Read

Fair Value

$1.08

Estimated downside of 20.3% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

Comps Fair Value

$1.08

Comparable-company valuation reference.

Analyst Price Target

$8.33

Analysts imply upside of 512.7%.

How to read these valuation models

Use the 4 available valuation references for OKYO Pharma (NASDAQ-OKYO) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for OKYO Pharma (NASDAQ-OKYO)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-8.498 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review OKYO Pharma (NASDAQ-OKYO) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for OKYO Pharma (NASDAQ-OKYO)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Altman Z-Score

-17.7

Lower score that deserves closer risk review.

FCF / Net Income

66.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for OKYO Pharma (NASDAQ-OKYO). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for OKYO Pharma (NASDAQ-OKYO)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

December 2, 2026

Days to Earnings

75

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for OKYO Pharma (NASDAQ-OKYO), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

OKYO Pharma (NASDAQ-OKYO) Stock Forecast & Technical Outlook

Review OKYO Pharma (NASDAQ-OKYO) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for OKYO Pharma (NASDAQ-OKYO) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for OKYO Pharma (NASDAQ-OKYO) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for OKYO Pharma (NASDAQ-OKYO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for OKYO Pharma (NASDAQ-OKYO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for OKYO Pharma (NASDAQ-OKYO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for OKYO Pharma (NASDAQ-OKYO)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, OKYO Pharma (NASDAQ-OKYO) has a Strong Buy consensus, with 2 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 0
Sell 0
FAQ • Fast Investor Answers

OKYO Pharma (NASDAQ-OKYO) Stock FAQ

Data-supported answers about OKYO Pharma (NASDAQ-OKYO), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.08
Estimated downside 20.3%
Valuation Rating
Overvalued
Estimated downside of 20.3%
Analyst Target
$8.33
Implied upside 512.7%
Financial Health
Fair
Current financial-health read

The current fair value estimate for OKYO Pharma (NASDAQ-OKYO) is $1.08. This implies an estimated downside of 20.3% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 20.3% versus the current market price.

The available analyst price target for OKYO Pharma (NASDAQ-OKYO) is $8.33. The analyst target implies estimated upside of 512.7%.

The current financial health read for OKYO Pharma (NASDAQ-OKYO) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for OKYO Pharma (NASDAQ-OKYO) is December 2, 2026.

The latest available data indicates no current dividend yield for OKYO Pharma (NASDAQ-OKYO).

The current market capitalization listed for OKYO Pharma is 70.585 M.

The current enterprise value listed for OKYO Pharma is 50.778 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for OKYO Pharma is NASDAQ-OKYO, and the stock is listed on NASDAQ.

OKYO Pharma (NASDAQ-OKYO) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for OKYO Pharma is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for OKYO Pharma is 53.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B